SCHEMBL7508553

SCHEMBL7508553

Cc1ccc(-c2cn3cc(C)cnc3n2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 13/20 0.62
KDM4E B2RXH2 11/20 0.62
ALDH1A1 P00352 11/20 0.62
NPC1 O15118 10/20 0.62
GAA P10253 7/20 0.62
KMT2A Q03164 5/20 0.62
MEN1 O00255 3/20 0.62
SMN1; SMN2 Q16637 9/20 0.59
MITF O75030 2/20 0.59
PAX8 Q06710 2/20 0.59
KDM5A P29375 1/20 0.59
KDM5C P41229 1/20 0.59
MAPT P10636 4/20 0.52
APP P05067 3/20 0.52
HPGD P15428 6/20 0.49
TP53 P04637 4/20 0.49
HSD17B10 Q99714 4/20 0.49
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49
ALDH1A3 P47895 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13290937 0.89 RAB9A (0.60) RAB9AKDM4EALDH1A1NPC1GAA
SCHEMBL13290931 0.88 KDM4E (0.57) RAB9AKDM4EALDH1A1NPC1GAA
SCHEMBL13290926 0.86 APP (0.72) RAB9AKDM4EALDH1A1NPC1GAA
SCHEMBL2538990 0.85 RAB9A (0.72) RAB9AKDM4EALDH1A1NPC1GAA
SCHEMBL2536926 0.85 APP (0.72) RAB9AKDM4EALDH1A1NPC1GAA
SCHEMBL22393194 0.81 GRM5 (0.47) RAB9AKDM4EALDH1A1NPC1GAA
SCHEMBL22403253 0.78 RAB9A (0.47) RAB9AKDM4EALDH1A1NPC1GAA
SCHEMBL17626882 0.77 ALDH1A1 (1.00) RAB9AKDM4EALDH1A1NPC1GAA
SCHEMBL13290930 0.76 APP (0.47) RAB9AKDM4EALDH1A1NPC1GAA
SCHEMBL22393188 0.75 RAB9A (0.45) RAB9AKDM4EALDH1A1NPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100143251-A1 COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES MOLECULAR NEUROIMAGING, LLC 2010-06-10 US disclosed
EP-1259509-A1 PROCESS FOR THE PREPARATION OF 6-METHYL-2-(4-METHYL-PHENYL)-IMIDAZO 1,2-A]PYRIMIDINE-3-(N,N-DIMETHYL-ACETAMIDE) AND INTERMEDIATES EGIS GYOGYSZERGYAR RT. (HU) 2002-11-27 EP disclosed
WO-2001038327-A2 PROCESS FOR THE PREPARATION OF 6-METHYL-2-(4-METHYL-PHENYL)-IMIDAZO[1,2-A]PYRIMIDINE-3-(N,N-DIMETHYL-ACETAMIDE) AND INTERMEDIATES EGIS Gyógyszergyár Rt. (HU) 2001-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143251-A1 COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES APP, BACE1, BACE2 RAB9A 4657/4885KDM4E 4389/4885ALDH1A1 1882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.